Wockhardt Ltd — Capital/Financing Update 2022

Feb 8, 2022

8[th] February, 2022

==> picture [178 x 49] intentionally omitted <==

Ref. No.: WOCK/SEC/SE/2021-22/127

BSE Limited Corporate Relations Department P J Towers, Dalal Street Mumbai - 400 001 Scrip Code: 532300

National Stock Exchange of India Limited Listing Department Exchange Plaza Bandra Kurla Complex, Bandra (E), Mumbai - 400 051 NSE Symbol – WOCKPHARMA

Dear Sir/ Madam,

Sub: Press Release

Please find enclosed herewith the Press Release titled “ Wockhardt gets CDSCO nod for exporting up to 100 million doses of Sputnik Vaccines” , which is self-explanatory.

Kindly take the above information on record.

Thanking you,

For Wockhardt Limited

==> picture [115 x 56] intentionally omitted <==

Debashis Dey Company Secretary Encl: As above

==> picture [112 x 49] intentionally omitted <==

==> picture [513 x 32] intentionally omitted <==

Wockhardt Limited Registered Office: D-4, MIDC, Chikalthana Aurangabad - 431006, India Tel.: +91-22-2653 4444 CIN: L24230MH1999PLC120720 www.wockhardt.com

==> picture [143 x 31] intentionally omitted <==

==> picture [225 x 36] intentionally omitted <==

Mumbai, 8[th] February 2022

Wockhardt gets CDSCO nod for exporting up to 100 million doses of Sputnik Vaccines

Wockhardt Limited, a global Pharmaceutical and Biotechnology Company headquartered in India, on Tuesday said that it has received permission from the Central Drugs Standard Control Organization (CDSCO) to export up to 80 million doses of Sputnik Light and up to 20 million doses of Sputnik V Component I vaccine.

Wockhardt’s Bulk vaccine and Fill-Finish manufacturing facilities at Waluj and Shendra, Aurangabad respectively were jointly inspected and approved by Drug inspectors from CDSCO (West zone) & Aurangabad State FDA and Expert from CDL Kasauli to receive export NOC.

Wockhardt’s state-of-the-art automated manufacturing facilities in Aurangabad are dedicated to produce world class high quality injectable products.

Wockhardt has entered into an agreement with Russian Direct Investment Fund and Enso Healthcare to manufacture and supply Sputnik V and Sputnik Light vaccines against COVID-19 based on the technology transfer from Gamaleya National Research Institute of Epidemiology and Microbiology.

About Wockhardt:

Wockhardt is a research based Global Pharmaceutical and Biotech Company. Wockhardt’s New Drug Discovery programme has focussed on unmet need of Anti-bacterial drugs that are effective against the menace of untreatable superbugs. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified Infectious Disease Product) for 6 of our Anti-bacterial discovery programmes – 3 of them are Gram Negative and 3 Gram Positive effective against untreatable “Superbugs”. It has a comprehensive Drug Discovery team and clinical organisation.

Wockhardt is employing over 5000 people and 27 nationalities with presence in USA, UK, Ireland, Switzerland, France, Mexico, Russia and many other countries. It has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. Wockhardt has a significant presence in USA, Europe and India, with 81% of its global revenues coming from international businesses.

For more information, please contact:

Mr. Debashis Dey E-mail: investorrelations@wockhardt.com